- Home
- SHOO vs TARS Comparison
SHOO vs TARS Comparison
Compare SHOO & TARS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SHOO | TARS |
|---|---|---|
| Founded | 1990 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Shoe Manufacturing | Medicinal Chemicals and Botanical Products |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.8B |
| IPO Year | 1996 | 2020 |
Fundamental Metrics
Financial Performance| Metric | SHOO | TARS |
|---|---|---|
| Price | $31.35 | $67.78 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 7 | 6 |
| Target Price | $42.43 | ★ $89.00 |
| AVG Volume (30 Days) | ★ 1.4M | 562.0K |
| Earning Date | 05-28-2026 | 06-01-2026 |
| Dividend Yield | ★ 2.58% | N/A |
| EPS Growth | N/A | ★ 48.21 |
| EPS | ★ 0.63 | N/A |
| Revenue | ★ $2,534,109,000.00 | $451,360,000.00 |
| Revenue This Year | $12.27 | $56.26 |
| Revenue Next Year | $5.87 | $26.47 |
| P/E Ratio | $51.82 | ★ N/A |
| Revenue Growth | 11.00 | ★ 146.71 |
| 52 Week Low | $19.05 | $38.51 |
| 52 Week High | $46.88 | $85.25 |
Technical Indicators
Market Signals| Indicator | SHOO | TARS |
|---|---|---|
| Relative Strength Index (RSI) | 27.97 | 42.63 |
| Support Level | $23.21 | $65.62 |
| Resistance Level | $35.98 | $78.34 |
| Average True Range (ATR) | 1.60 | 3.13 |
| MACD | -0.24 | -0.55 |
| Stochastic Oscillator | 0.72 | 3.58 |
Price Performance
Historical ComparisonAbout SHOO Steven Madden Ltd.
Steven Madden Ltd designs and sells brand-name and private-label footwear and accessories. Its products are geared toward fashion-conscious adults and children. The company sells its products through department stores and other retailers as well as its stores and websites. The company's revenue comes from its operating segments: Wholesale Footwear, Wholesale Accessories or Apparel, Direct-to-Consumer, and Licensing. The wholesale footwear segment accounts for the majority of revenue.
About TARS Tarsus Pharmaceuticals Inc.
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. The company is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis.